Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CRNX | DEFA14A | bullish | 7/10 | Crinetics Pharmaceuticals filed this DEFA14A as soliciting material in connection with its pending merger with Vertex Ph | Jul 10, 2026 |
| CYCN | 425 | mixed | 6/10 | Cyclerion Therapeutics (CYCN) filed a Korsana Biosciences investor presentation in connection with their proposed revers | Jul 10, 2026 |
| CALC | 3 | neutral | 2/10 | Alafi Capital Co LLC filed a Form 3 initial statement of beneficial ownership with the SEC, disclosing ownership of 5,11 | Jul 10, 2026 |
| MRNA | 3 | neutral | 2/10 | Michael McDonnell filed a Form 3 initial statement of beneficial ownership with Moderna, indicating he has become an off | Jul 10, 2026 |
| NAGE | 424B5 | bearish | 6/10 | Niagen Bioscience filed a 424B5 prospectus supplement for an at-the-market offering of up to $50 million in common stock | Jul 10, 2026 |
| VRXA | PRESS-RELEASE | neutral | 3/10 | VERAXA Biotech appointed Carl von Halem as Interim CFO, succeeding Torsten Bürgermeister. The company is in late-stage d | Jul 10, 2026 |
| ZSQR | 8-K | bearish | 6/10 | Z Squared Inc. amended its LOI to acquire Skycore Digital LLC, extending the drop dead date to January 15, 2027, elimina | Jul 10, 2026 |
| SBFM | 8-K | neutral | 4/10 | Sunshine Biopharma settled a dispute with former president Malek Chamoun for CAD$1,500,000 (US$1,058,565), avoiding liti | Jul 10, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | CEO Martine Rothblatt and EVP Paul Mahon sold a combined $366K in open-market sales over a 7-day window. The CEO's sales | Jul 10, 2026 |
| INM | 8-K | bearish | 6/10 | InMed Pharmaceuticals entered into Amendment No. 1 to its merger agreement with Mentari Therapeutics, clarifying deal se | Jul 10, 2026 |
| TRAW | 424B5 | bearish | 6/10 | Traws Pharma filed a 424B5 prospectus supplement to sell up to $5.6M of common stock via an at-the-market (ATM) offering | Jul 10, 2026 |
| SUIC | 8-K | mixed | 6/10 | SUIC Worldwide Holdings Ltd. completed a share-exchange acquisition of 51% of Vision Renu Corporation, issuing 30 millio | Jul 10, 2026 |
| RVPH | 25-NSE | bearish | 7/10 | Nasdaq has filed a Form 25-NSE to remove Reviva Pharmaceuticals Holdings, Inc. from listing and registration, effective | Jul 10, 2026 |
| SAFX | 3 | neutral | 2/10 | Wray T. Thorn filed a Form 3 initial statement of beneficial ownership, disclosing indirect ownership of 3,306,944 share | Jul 10, 2026 |
| MIRA | 8-K | neutral | 3/10 | MIRA Pharmaceuticals announced positive preclinical results for lead oral formulation of MIRA-55, demonstrating favorabl | Jul 10, 2026 |
| SLBT | 6-K | neutral | 4/10 | SL Science has submitted an Orphan Drug Designation (ODD) request to the FDA for its GDT cell therapy targeting glioblas | Jul 10, 2026 |
| VYNE | 425, 8-K | neutral | 5/10 | VYNE Therapeutics declared a special cash dividend of an estimated $16.5 million ($0.38 per share) in connection with it | Jul 10, 2026 |
| GSK | 6-K | bullish | 5/10 | GSK announced positive phase III overall survival data for its B7-H3-targeted ADC risvutatug rezetecan (Ris-Rez) in adva | Jul 10, 2026 |
| RDY | 6-K | neutral | 2/10 | Dr. Reddy's filed a Form 6-K furnishing Exhibit 99.1, an intimation letter to stock exchanges providing a weblink to the | Jul 10, 2026 |
| ALMR | PRESS-RELEASE | bullish | 5/10 | Alamar Biosciences announced that its NULISA platform will be featured in over 140 poster and session presentations at t | Jul 10, 2026 |
| AKTS | CLUSTER | neutral | 4/10 | Two C-suite insiders at Aktis Oncology (COO and CMO) executed near-simultaneous option-exercise-and-sell transactions on | Jul 10, 2026 |
| OTLK | DEFA14A | neutral | 4/10 | Outlook Therapeutics filed a DEFA14A supplement to its proxy statement, updating shareholders that it regained Nasdaq mi | Jul 10, 2026 |
| ORGN | EFFECT | bearish | 6/10 | Origin Materials has received effectiveness on two shelf registration statements (File Nos. 333-289615 and 333-257931) o | Jul 10, 2026 |
| TRAW | EFFECT | bearish | 7/10 | Traws Pharma's S-3 shelf registration (filing 333-297195) became effective on July 9, 2026, allowing the company to sell | Jul 10, 2026 |
| NAGE | EFFECT | bearish | 6/10 | The SEC declared effective Niagen Bioscience's S-3 shelf registration (File No. 333-297093) on July 9, 2026, clearing th | Jul 10, 2026 |
| MESO | 6-K | bullish | 7/10 | Mesoblast reported Ryoncil net revenue of US$36M for Q4 and US$115M for FY2026 ending June 30, 2026. The filing is a pre | Jul 10, 2026 |
| IONS | 8-K | neutral | 2/10 | Ionis Pharmaceuticals filed an 8-K reaffirming its previously announced FY2026 financial guidance from April 29, 2026, w | Jul 10, 2026 |
| ANVS | 8-K | neutral | 6/10 | Annovis Bio announced full enrollment of its pivotal Phase 3 trial (NCT06709014) of buntanetap for early Alzheimer's dis | Jul 10, 2026 |
| HALO | CLUSTER | neutral | 2/10 | CEO Helen Torley sold $153K in stock after exercising derivative shares at $12.07, netting a substantial cashless-settle | Jul 10, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | CEO Martine Rothblatt sold ~$7.7M in open-market shares over July 8-9, 2026, following option exercises. EVP Paul Mahon | Jul 10, 2026 |